A. SENP1
lox/lox mice were generated based on homologous recombination. SENP1 lox/lox mice were mated with SM22α Cre to obtain smooth muscle-specific SENP1-deficient (SENP1 lox/lox -SM22 Cre) mice.
B. Generation of SENP1
lox/lox (WT) and SENP1 lox/lox -SM22Cre (SENP1smKO) mice. Tail genomic DNA was used to determine SENP1 deletion by PCR with KO primers adjacent to 5' of lox P1 (KO1) and lox P3 (KO2) to obtain heterozygous mice with a deletion of both the targeting region (the exons 5/6) and the Neo gene (SENP1 +/-). SENP1 KO mice were obtained by intercrossing between the heterozygous (SENP1 +/-) male and female. Representative genotypes are shown.
C. SENP1 was determined by qRT-PCR in uterus of WT and SENP1smKO mice at P21.
D. SENP1 deletion in the stroma, but not the epithelium layer of uterus. SENP1 was stained with anti-SENP1 antibody followed by DAPI counterstaining in uterus of WT and SENP1smKO mice at P21. 100 E. Cyclin D1 mRNA expression was determined by qRT-PCR in uterus from 4-month WT and SENP1smKO mice.
F-G.
Cyclin D1 protein expression and quantification in uterine from 4-month WT and SENP1smKO mice by Western blotting. GAPDH was used as a loading control.
All data are presented as means ± SEM, n=5, **, P<0.01 ***, P<0.001 (two-sided student's t-test). A. Immunofluorescent staining of CD34, SM22αand SUMO1 in human endometrial cancer samples. 
